Workflow
药店
icon
Search documents
益丰药房(603939) - 益丰药房关于2025年半年度主要经营数据的公告
2025-08-28 08:22
证券代码:603939 证券简称:益丰药房 公告编号:2025-081 债券代码:113682 债券简称:益丰转债 益丰大药房连锁股份有限公司 关于2025年半年度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据上海证券交易所发布的上市公司分行业信息披露指引及《关于做好主板 上市公司 2025 年半年度报告披露工作的通知》相关要求,现将益丰大药房连锁 股份有限公司(以下简称"公司")2025 年半年度主要经营数据披露如下: 一、报告期末主要经营数据 1、主要会计数据 单位:元 币种:人民币 | 主要会计数据 | 本报告期 | 上年同期 | 本报告期比上 年同期增减 | | --- | --- | --- | --- | | | (1-6月) | | | | | | | (%) | | 营业收入 | 11,721,819,634.46 | 11,762,401,111.51 | -0.35 | | 归属于上市公司股东的净利润 | 880,045,883.20 | 797,718,135.20 | 1 ...
益丰药房:2025年上半年净利润同比增长10.32%
Xin Lang Cai Jing· 2025-08-28 07:48
Core Viewpoint - The company reported a slight decline in revenue for the first half of 2025, while net profit showed a positive growth trend [1] Financial Performance - The company's operating revenue for the first half of 2025 was 11.722 billion yuan, representing a year-on-year decrease of 0.35% [1] - The net profit for the same period was 880 million yuan, reflecting a year-on-year increase of 10.32% [1] Dividend Distribution - The company plans to distribute a cash dividend of 0.30 yuan per share (including tax) to all shareholders based on the total share capital as of the dividend record date for the first half of 2025 [1] - The total cash dividend payout is expected to be 364 million yuan (including tax) [1]
达嘉维康:旗下各零售药店有驱蚊手环等驱蚊类产品的销售
Zheng Quan Ri Bao· 2025-08-27 10:53
Group 1 - The company, Dajia Weikang, has confirmed the sale of mosquito repellent products through its retail pharmacies, including mosquito repellent bracelets, patches, and sprays [2]
中信证券:商保创新药目录进入实质性落地阶段 建议关注镁信健康、思派等综合服务提供商
Zhi Tong Cai Jing· 2025-08-27 02:29
Core Viewpoint - The initiation of the commercial insurance innovation drug directory adjustment by the National Medical Insurance Administration marks a significant step towards the practical implementation of commercial insurance innovation drug coverage, potentially leading to a revaluation of the healthcare industry [1][2] Group 1: Investment Opportunities - The healthcare industry is expected to experience a "Davis Double Hit," with a restructured valuation system due to the introduction of the commercial insurance innovation drug directory [1] - Three main investment themes are suggested: 1. Innovative drugs and medical devices, which are likely to benefit from increased payment amounts from commercial insurance [1] 2. Comprehensive service providers that enhance insurance companies' product design capabilities and negotiation power for medical products [1][2] 3. Differentiated medical terminals that could open up future growth opportunities and elevate valuation levels [1] Group 2: Market Growth Projections - From 2023 to 2030, the payment amount from commercial health insurance for innovative drugs and medical devices is projected to grow from 7.3 billion to 126.2 billion, with a compound annual growth rate (CAGR) of 50.3% [1] - The introduction of the commercial health insurance directory is expected to increase the usage rate of innovative drugs and medical devices in hospitals, thereby encouraging upstream innovation [1] Group 3: Comprehensive Service Providers - Comprehensive service providers are anticipated to benefit from the commercial insurance innovation drug directory by offering solutions such as clinical value analysis and marketing to insurance companies, as well as consulting and medical inquiry services to insurance clients [2] - Companies like Sipai Health (00314) and Shanghai Pharmaceuticals (601607) with its subsidiary Meixin Health are highlighted as potential beneficiaries [2] Group 4: Multi-layered Payment System - The expansion of commercial health insurance is expected to enhance China's multi-layered payment system, unlocking potential in diverse medical needs that were previously limited [2] - New payment sources are likely to emerge for medical terminals and pharmacies, creating future growth opportunities for medical service companies and the pharmacy sector [2]
益丰大药房连锁股份有限公司2025年第二次临时股东会决议公告
Meeting Overview - The second extraordinary general meeting of shareholders was held on August 25, 2025, at the Yifeng Pharmaceutical Logistics Park in Changsha, Hunan Province [2] - The meeting was conducted through a combination of on-site and online voting, presided over by Chairman Gao Yi, and complied with relevant laws and regulations [2][3] Attendance - All 9 current directors and 3 current supervisors attended the meeting, along with the board secretary and some other senior executives [3] Resolutions Passed - The following proposals were approved during the meeting: 1. Proposal to abolish the supervisory board and amend the Articles of Association [4] 2. Proposal to amend the Board Meeting Rules [5] 3. Proposal to amend the Independent Director Work System [5] 4. Proposal to amend the External Guarantee Management System [5] 5. Proposal to amend the External Investment Management System [5] 6. Proposal to amend the Shareholders Meeting Rules [5] 7. Proposal to amend the Related Party Transaction Management System [5] 8. Proposal to amend the Fundraising Management System [6] 9. Proposal to add a system for the resignation of directors and senior management [6] 10. Proposal for the company to provide guarantees for bank credit applications by subsidiaries [6] Special Resolutions - Three special resolutions, including the proposal to abolish the supervisory board, received more than two-thirds approval from the shareholders present [6] Employee Representative Director Election - An employee representative meeting was held on August 25, 2025, where Gao Youcheng was elected as the employee representative director, with a term lasting until the end of the fifth board's term [7][8] Senior Management Departure - Vice President Zhang Jia submitted a resignation report due to personal reasons and will not hold any other positions within the company post-resignation [11] - The company has made arrangements to ensure that Zhang Jia's departure will not affect normal operations, and the board expressed gratitude for his contributions during his tenure [12]
老百姓: 老百姓《内部审计制度》(2025年8月修订)
Zheng Quan Zhi Xing· 2025-08-25 16:31
第一条 为明确审计工作的性质、使命和目标,明确老百姓大药房连锁股份有限公司(以 下简称"公司")内部审计机构的职责与权限,确保董事会对经理层的有效监督,发挥内部 审计在强化内部控制、改善经营管理、提高经济效益中的促进和保证作用,以维护投资者的 权益,实现审计的制度化和规范化,根据《中华人民共和国公司法》《中华人民共和国审计 法》《上海证券交易所股票上市规则》《上海证券交易所上市公司自律监管指引第 1 号—— 规范运作》和《老百姓大药房连锁股份有限公司章程》(以下简称"《公司章程》"),特 制定本制度。 第二条 本制度所称内部审计,是指公司内部审计机构或人员在法律法规、公司规定和董 事会批准范围内,通过运用系统、规范的方法,对公司内部控制和风险管理的适当性和有效 性以及业务活动运行的效率和效果等开展的独立、客观的评价和咨询活动。 第三条 内部审计应遵循"独立、客观、公正"的原则,保证其工作合法、合理、有效, 完善公司内部约束机制,加强内部管理,提高经济效益。 第二章 内部审计机构及人员 老百姓大药房连锁股份有限公司 内部审计制度 (二〇二五年八月二十五日,第五届董事会第十次会议审议通过) 第一章 总则 第四条 ...
老百姓: 老百姓《信息披露事务管理制度》(2025年8月修订)
Zheng Quan Zhi Xing· 2025-08-25 16:31
Core Points - The document outlines the information disclosure management system of the company, aiming to ensure timely, fair, truthful, accurate, and complete information disclosure to protect investors' rights [1][2][3] - The company is committed to proactive disclosure of significant information that may impact stakeholders' decisions, while safeguarding sensitive financial data and trade secrets [1][2] Group 1: General Principles - The company establishes information disclosure principles in accordance with relevant laws and regulations, including the Company Law and Securities Law [1][2] - Information disclosure must be conducted through designated channels, ensuring accessibility for the public [1][2] Group 2: Disclosure Formats and Content - Regular reports, including annual and interim reports, must be disclosed within specified timeframes, with annual reports due within four months after the fiscal year-end and interim reports within two months after the first half of the fiscal year [2][3] - The content of annual reports includes company basic information, major accounting data, stock and bond issuance details, shareholder information, and significant events affecting the company [2][3][4] Group 3: Responsibilities and Procedures - The board of directors must approve regular reports, and financial information must be audited by a qualified accounting firm [4][5] - The company must disclose significant events that could impact stock prices immediately, detailing the event's cause, current status, and potential effects [6][12] Group 4: Management of Disclosure - The company's securities affairs department is responsible for managing daily disclosure tasks and ensuring compliance with regulations [34][35] - The board secretary plays a crucial role in coordinating disclosure activities and ensuring that all relevant information is accurately reported [35][36] Group 5: Confidentiality and Compliance - Individuals with access to undisclosed information are considered insiders and must maintain confidentiality to prevent unauthorized trading [58][59] - The company must implement measures to control the dissemination of insider information and ensure compliance with regulatory requirements [60][61]
老百姓: 湖南启元律师事务所关于老百姓大药房连锁股份有限公司2022年限制性股票激励计划回购注销剩余限制性股票及调整回购价格的法律意见书
Zheng Quan Zhi Xing· 2025-08-25 16:31
湖南启元律师事务所 关于老百姓大药房连锁股份有限公司 限售期及预留授予部分第二个解除限售期解除限售条 件未成就及回购注销剩余限制性股票、调整回购价格 的 法律意见书 湖南省长沙市芙蓉区建湘路 393 号世茂环球金融中心 63 层 410000 电话:(0731)82953-778 传真:(0731)82953-779 网站:www.qiyuan.com 致:老百姓大药房连锁股份有限公司 湖南启元律师事务所(以下简称"启元"或"本所")接受老百姓大药房连 锁股份有限公司(以下简称"老百姓""公司"或"上市公司")的委托,担任 老百姓 2022 年限制性股票激励计划(以下简称"本次激励计划""本激励计划" 或"激励计划")的专项法律顾问。 本所律师根据《中华人民共和国公司法》(以下简称"《公司法》")、《中 华人民共和国证券法》(以下简称"《证券法》")、《上市公司股权激励管理 办法》(以下简称"《管理办法》")等现行法律、法规和规范性文件以及《老 百姓大药房连锁股份有限公司章程》(以下简称"《公司章程》")、《老百姓 大药房连锁股份有限公司 2022 年限制性股票激励计划(草案)》 (以下简称"《激 励计划(草 ...
益丰药房: 益丰药房2025年第二次临时股东会决议公告
Zheng Quan Zhi Xing· 2025-08-25 16:30
证券代码:603939 证券简称:益丰药房 公告编号:2025-077 债券代码:113682 债券简称:益丰转债 益丰大药房连锁股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: ? 本次会议是否有否决议案:无 一、 会议召开和出席情况 (一)股东会召开的时间:2025 年 8 月 25 日 (二)股东会召开的地点:湖南省长沙市金洲大道 68 号益丰医药物流园三楼 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况: 本次会议采取现场投票和网络投票相结合的方式召开,公司董事会召集本次 会议,董事长高毅先生主持。本次会议的召集、召开和表决方式符合《公司法》 《上海证券交易所股票上市规则》《公司章程》和公司《股东大会议事规则》的 规定,合法有效。 (五)公司董事、监事和董事会秘书的出席情况 二、 议案审议情况 (一)非累积投票议案 审议结果:通过 表决情况: 股东类型 同意 反对 弃权 票数 比例 票数 比例 票数 比例 (%) (%) (%) A股 904,166,756 99.967 ...
一心堂:目前以提升存量门店经营质量为主
证券日报网讯 一心堂8月22日在互动平台回答投资者提问时表示,公司目前以提升存量门店经营质量为 主,现有门店进行转型升级,增加非药品类,在保证合规经营的前提下,为消费者提供更加广泛和全面 的大健康消费产品,以此带动客流和销售额的增长。 (编辑 王雪儿) ...